Osteoimmunomodulation for the development of advanced bone biomaterials by Chen, Zetao et al.
R
E
S
E
A
R
C
H
:
R
eviewMaterials Today  Volume 19, Number 6  July/August 2016 RESEARCH
Osteoimmunomodulation for the
development of advanced bone
biomaterials
Zetao Chen1,3, Travis Klein1,3, Rachael Z. Murray1, Ross Crawford1,3,
Jiang Chang2,3, Chengtie Wu2,3,* and Yin Xiao1,3,*
1 Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, 60 Musk Ave, Kelvin Grove, Brisbane, Queensland 4059, Australia
2 State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi
Road, Shanghai 200050, People’s Republic of China
3Australia-China Centre for Tissue Engineering and Regenerative Medicine, Queensland University of Technology, Brisbane, 60 Musk Ave, Kelvin Grove, Brisbane,
Queensland 4059, Australia
As direct effector cells for osteogenesis, osteoblastic cells are commonly used for evaluating the in vitro
osteogenic capacity of bone biomaterials, and the traditional biological principle for developing bone
biomaterials is to directly stimulate osteogenic differentiation. With this principle, most efforts are
currently spent on optimizing the bio-mechanical and physicochemical properties to induce osteogenic
differentiation of mesenchymal stem cells. This strategy has achieved certain success in the development
of bone biomaterials; however, inconsistencies between in vitro and in vivo studies are not uncommon,
implying the mechanisms that govern the material’s capacity to mediate osteogenesis is not well-
understood. Osteoimmunology has revealed the vital role of immune cells in regulating bone dynamics.
Neglecting the importance of the immune response is a major shortcoming of the traditional strategy,
and may explain inconsistencies between in vitro and in vivo conditions. Here, we proposed
osteoimmunomodulation (OIM) in recognition of the importance of the immune response during
biomaterial-mediated osteogenesis. Accordingly, we proposed the paradigm shift of bone biomaterials
to an osteoimmunomodulatory material and discussed the evaluation strategy for the
osteoimmunomodulation property of bone biomaterials. It is the ambition of authors that this review
will change traditional methods for bone biomaterials assessment and assist in developing new bone
biomaterials with the osteoimmunomodulatory property for orthopedic and dental applications.Introduction
Bone defects caused by tumor resection, traumatic fracture, aseptic
necrosis, osteolysis, osteomyelitis, periodontitis, and spinal fu-
sion, to name but a few, typically require surgical remediation
using bone biomaterials [1–4]. Due to the direct relationship
between osteoblastic lineage and bone formation, the major prin-
ciple for developing bone biomaterials is to manipulate the in vitro
osteogenic differentiation of the osteoblastic lineage and then
investigating the potential osteogenic biomaterials in an in vivo
model. With this principle, many strategies have been developed*Corresponding authors: Wu, C. (chengtiewu@mail.sic.ac.cn), Xiao, Y. (yin.xiao@qut.edu.au)
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osseointegration and osteogenesis. The fabrication techniques
are quite advanced that materials scientists can somehow prepare
bone biomaterials with the desired physicochemical and mechan-
ical properties (from nano to particle size, from 2D to customized
3D structure, from hydrophilic to hydrophobic, etc.).
However, this principle often does not lead to clinically useful
bone implant materials, with many candidates failing to make it
beyond the confines of the laboratory. When analyzing the
possible reasons, we focus on optimizing the compositions, the
bio-physicochemical and mechanical properties of the candidate
materials, but we rarely think that perhaps the basic biologicalhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/
j.mattod.2015.11.004
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progress and the mechanisms underlying osteogenesis have been
much better understood. We now know that osteogenesis is not
simply accomplished by bone cells from skeleton system, but a
collaboration of multiple systems. This indicates that the tradi-
tional biological principle is outdated and insufficient, which
could be a leading reason for the failure of trials. To fabricate
an ideal bone biomaterial, we need to keep the pace with the
development of bone biology and keep on modifying the basic
biological principle.
Among all the achievements made in the area of bone biology,
the development of osteoimmunology is one of the greatest. The
immune and skeletal systems are found to be closely related,
sharing a number of cytokines, receptors, signaling molecules
and transcription factors [5,6]. Immune cells play a key role in
bone homeostasis. Being a foreign body, an implant is recognized
by the immune system and triggers a significant immune reaction
that affects the biological behavior of bone cells. Such an event
may eventually determine the in vivo fate of bone biomaterials
[7,8]. The immune response may, therefore, be a key factor that is
neglected when evaluating the osteogenic capacity of bone bio-
materials. Accordingly, the design paradigm for advanced bone
biomaterials should be shifted from being relatively inert to hav-
ing immunomodulatory properties, emphasizing the important
role of immune responses [7]. A new generation of bone bioma-
terials should be able to modulate the local immune environment
such that it favors osteogenesis and the osseointegration of the
implant.
Developing such biomaterials would require an in-depth un-
derstanding of a number of important issues. Firstly, it is impor-
tant to understand the relationship between immune cells and
bone cells and what effect the immune environment induced by
implanted biomaterials has on osteogenesis. Secondly, the mech-
anisms underlying the material-mediated immune response must
be understood in order to aid the design and preparation of
biomaterials to induce an immune environment that provides
conditions that balance osteogenesis and osteoclastogenesis for
optimal osseointegration. Finally, determining whether or not a
biomaterial can induce a favorable immune response should be a
routine screening process and part of a standard evaluation proto-
col when developing advanced immunomodulatory bone bioma-
terials. In this review, we define such a capacity as
osteoimmunomodulation (OIM) – a novel property of bone bio-
materials. Favorable OIM properties are of great importance when
attempting to produce advanced bone biomaterials for clinical
application with optimal osteogenesis and osseointegration.
Overview of the integration between bone tissue and
implants
The mechanism underlying bone biomaterial-mediated osteogen-
esis involves at least three interactive components: the host im-
mune cells, the host bone cells and the materials. Following
implantation, the host body will first undergo a universal response
to the materials, which is an extension of the mammalian response
following tissue injury [9]. Proteins from blood and interstitial
fluids, such as fibrinogen, vitronectin, complement, and fibronec-
tion [7], will adsorb to the material’s surfaces within seconds and
then form a transient surface matrix. In response, the coagulationcascade and complement systems are activated, leading to throm-
bus formation and activation of other cell populations.
After the initial blood/material interaction, an acute inflamma-
tion is initiated, which features the recruitment and activation of
neutrophils, or polymorphonuclear leukocytes (PMNs). PMNs, in
an effort to degrade the materials, release proteolytic enzymes and
reactive oxygen species (ROS) [10], which will corrode the surface
of the material. The PMNs rapidly become exhausted, undergoing
apoptosis and disappearing from the implantation sites within the
first two days [11]. Mast cells are also active participants in the
acute inflammatory reaction and degranulation of these cells leads
to the release of inflammation-enhancing cytokines and hista-
mine, which amplify the immune reaction [12].
Chemoattractants and activation cytokines released in the pre-
vious phase result in monocyte recruitment to the implant, where
the cells differentiate into macrophages. Macrophages are able to
engulf particles of up to 5 mm [7,13]; if the particle size is larger, the
macrophages will coalesce to form foreign body giant cells
(FBGCs), driven by stimulation with IL-4 and IL-13 [14]. The
foreign components and molecules released during the host-
body/implant interaction can positively regulate osteogenic dif-
ferentiation to form new bone on the surface of the implant and
entrap it. In the bone remodeling phase newly formed bone
undergoes functional remodeling and some entrapped implant
materials, such as Ca–P based bioceramics, can be further degrad-
ed. Functional loading and the mechanical strain is the main cause
for the remodeling. Osteocytes are known to translate signals
related to mechanical strain into biochemical signals and regulate
osteoblasts and osteoclasts and, therefore, may play a regulatory
role in this late stage [15–17] (Fig. 1a).
The close relationship that exists between the immune and
skeletal systems makes the proposition that stimulated immune
cells may contribute to both the success and failure of an implant
seem feasible (Fig. 1). The immune cells would exert this effect by
releasing cytokines that regulate osteogenesis, in addition to their
well-known effects on inflammation, thus inducing or inhibiting
bone formation. The effects of the immune response to bone
biomaterials in regulating osteogenesis are, therefore, ‘a double-
edged sword’. A favorable immune reaction creates an osteogenic
microenvironment that can improve osteogenesis, whereas an
inappropriate immune reaction may lead to the chronic inflam-
mation and the formation of a fibrous capsule around the implant.
The capsule formed by the foreign body reaction (FBR) effec-
tively separates the implant from the surrounding environment,
such that it can remain safely in the host body throughout its
lifetime [18]. However, this renders the implant an ‘inert’ mechan-
ical support, a scenario which fails to meet the demands of a bone
substitute material since it is intended to induce new bone forma-
tion and fill the defect space with fully functional bone. A fibrous
encapsulation prevents direct interaction between bone marrow
and the implants such that bone cells cannot attach to the surface
of implants to form new bone. Instead, the defect will be filled by a
fibrous tissue, resulting in the failure of bone reconstruction. This
illustrates the importance of creating a local immune environment
that favors bone regeneration and osseointegration; manipulating
the immune response by targeted modifications of the bone
biomaterials is, therefore, a good strategy to swing the balance
toward this direction.305
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FIGURE 1
Schematic illustration of bone biomaterials mediated de novo bone formation (a) and the failure of bone biomaterials that lead to the fibrous encapsulation
(b). (a) This process can be divided into three phases: early, bone formation and remodeling phase, with the involvement of multiple systems: coagulation
system, immune system, skeleton system. The most likely macrophage phenotype switch pattern is also presented. The early stage of the repair response is
dominated by the inflammatory phase, when the majority of macrophages would be of the inflammatory M1 phenotype. An efficient and timely switch
from M1 to M2 macrophage phenotype results in an osteogenic cytokine release and with it the formation of new bone tissue. (b) It is also divided into
three phases: acute, chronic inflammation and fibrous encapsulation. The likely macrophage phenotype switch pattern is shown. The early stage is
dominated by the inflammatory phase, during which the majority of macrophages would be of the inflammatory M1 phenotype. However, a prolonged M1
polarization phase leads to an increase in fibrosis-enhancing cytokine release pattern by the M2 macrophages, which results in the formation of a
fibrocapsule. Adapted from [182].
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The field of osteoimmunology seeks to understand the interaction
between the immune and skeletal systems [6]. Immune cells
participate actively in bone physiology and pathology by releasing306regulatory molecules which elicit significant effects on osteoclas-
togenesis and osteogenesis (Fig. 2). Abnormal functioning of
immune cells can lead to an imbalance between osteoclasts and
osteoblasts and result in conditions such as osteolysis, osteoporo-
sis, osteoarthritis and rheumatoid arthritis. In this part, we will
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FIGURE 2
Schematic illustration of the role of immune cells in bone dynamics. Immune cells participate actively in osteoclastogenesis and osteogenesis by releasing
regulatory molecules.
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genesis and possible molecular mechanisms at play.
Immune cells and osteoclastogenesis
Immune cells regulate osteoclastogenesis by three major cyto-
kines: macrophage-colony stimulating factor (M-CSF), receptor
activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG).
M-CSF binds to its cognate receptor c-FMS on osteoclast precursors
and signals through the Akt and MAP kinase pathway [19]. RANKL
binds to RANK, a receptor on the surface of osteoclast precursors,
thereby transducing via TNF receptor associated factor 6 (TRAF6),
NF-kB, activator protein 1 (AP-1) and nuclear factor of activated T
cells 2 (NFAT2) to upregulate expression of genes for the survival
and differentiation of osteoclasts [5,20]. RANKL is expressed, not
only by osteoblastic cells that maintain normal osteoclastogenesis
in bone tissue, but also by activated T cells and neutrophils,
indicating the involvement of these immune cells during osteo-
clastogenesis [21,22]. Macrophages are the precursor of osteo-
clasts, which under the stimulation of M-CSF and RANKL can
differentiate into osteoclasts during bone remodeling.IL-6 and oncostatin M (OSM) are important mediators of osteo-
clast formation and function. IL-6 is known to induce the expres-
sion of RANKL, and utilize the RANKL/RANK-OPG system to elicit
indirect effects on promoting osteoclastogenesis and osteoclast
activation [23,24]. IL-6 is also found to participate in the TNF-a
and IL-l induced osteoclast formation [25]. OSM uses gp130, the
same receptor subunit as does IL-6, for signaling and these two
cytokines often have similar and overlapping functions [26]. OSM
can also stimulate the production of RANKL by osteoblasts and
enhance the formation of osteoclasts in a dose dependent manner,
which might be related to its synergistic effects with IL-6 [27,28].
By contrast, interferon-g (IFN g) promotes the degradation of
TRAF6, a key intermediate in RANKL/RANK pathway, thereby
preventing massive bone destruction during inflammation [5].
OPG, a decoy receptor for RANKL, interrupts the interaction of
RANKL/RANK, thereby inhibiting both differentiation and the
function of osteoclasts [29,30]. B cells have been shown to be a
major source of bone marrow-derived OPG [31,32], which implies
that B cells are one of the main inhibitor of osteoclastogenesis in
normal physiology. Depletion of CD4 and CD8 T lymphocyte307
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formation through a mechanism involving upregulated prosta-
glandin E production [32,33]. T-cells are found to work coopera-
tively with B-cells and increase OPG production by CD40/CD40L
co-stimulation, based on data showing that T-cell-deficient CD40
and CD40L-knock-out mice are osteoporotic [31].
Mast cells also participate actively in osteoclastogenesis [34]. A
reduction in the number of mast cells reduces bone remodeling,
whereas the enhancement of systemic mastocytosis leads to an
increase of bone loss [35,36]. Histamine, rather than pro-inflam-
matory cytokines, may be the major mediator during this interac-
tion; a study in mice showed that a targeted disruption of the
histidine decarboxylase gene, which leads to a deficiency of hista-
mine, had the effect of reducing bone loss, even in response to
ovariectomy [37,38].
The interaction between immune cells and osteoclast cells plays
a key role in the pathology of many bone diseases, such as
osteoarthritis, rheumatoid arthritis. Persistent excessive inflam-
mation is a feature of the continuous release of pro-inflammatory
cytokines (TNF-a, IL-1a/b and IL-6) and usually accompanies an
increased RANKL/OPG ratio and elevated osteoclast activity [39].
The result is a shift of bone remodeling toward osteoclast-mediat-
ed progressive bone erosions, characterized by derangement of
mineral and organic components, which results in excessive bone
loss and functional disability.
Immune cells and osteogenesis
Immune cells play an indispensable regulatory role in osteogenesis.
They can act positively in the progress of bone regeneration. Resi-
dent macrophages (osteomacs) are crucial for efficient osteoblast
mineralization, as depletion of macrophages leads to the complete
loss of osteoblast-mediating bone formation in vivo [40]. Bone
fracture healing is significantly enhanced in knockout mice that
lack T and B cells, indicating they may also have a detrimental
function during this process [41,42]. These data together suggest the
dual roles of immune cells in osteogenesis, through their expression
and secretion of a wide range of regulatory molecules [43], such as
inflammatory cytokines, bone morphogenetic protein 2 (BMP2),
transforming growth factor b (TGF-b), and vascular endothelial
growth factor (VEGF) [44,45]. A full understanding on how immune
cells and their secreted cytokines act on osteogenesis will help to
develop immunomodulatory intervention strategies that maximize
the regenerative and minimize the destructive effects of immune
response, leading to the desired bone regeneration.
A combination of four major inflammatory cytokines, TNF-a,
TGF-b, IFN-g, and IL-17 at physiological concentrations could
induce the production of mineralized matrix as effectively as
dexamethasone, a commonly used osteogenic medium supple-
ment [46]. TNF-a is found to increase alkaline phosphatase (ALP)
activity and mineralization by mesenchymal stromal cells (MSCs)
in a dose-dependent manner through activation of the NF-kB
signaling pathway [47,48]. The stimulatory effect of the condi-
tioned medium from the lipopolysaccharide (LPS)-activated in-
flammatory M1 macrophages on ALP activity is attenuated when
the conditioned medium is pretreated with TNF-a neutralizing
antibody [46]. It is also found that the knockout of IL-6 delays
callus maturity, mineralization, and remodeling indicating the
essential role of IL-6 in the early stages of fracture healing [49],308while the knockout of OSM in early stage leads to the reduced
amount of new bone [50].
However, the inhibitory effects of TNF-a have also been observed
on the differentiation of osteoblastic cells, by suppressing the release
of BMP2 and eliciting pro-apoptotic effects on osteoblasts [51,52].
The upregulation of IFN-g and TNF-a by T lymphocytes is also
thought to be responsible for the failure of MSCs based bone tissue
regeneration and its inhibitory effects can be eliminated by the
application of aspirin (an anti-inflammatory drug) [53]. The under-
lying mechanism may be related to the stimulation of NF-kB in
MSCs, which promotes degradation of b-catenin, thereby inhibiting
osteogenic differentiation [54]. This reasoning leads to the hypothe-
sis that the effects of inflammatory cytokines on osteogenesis may be
dose and time dependent and that an adequate concentration and
appropriate timing of these cytokines could induce osteogenesis. The
flip side to this is that inadequate concentrations and/or stimulation
time of the inflammatory cytokines may lead to bone resorption.
The observation that immune cells have an important role in
bone dynamics is a strong argument for considering the immune
responses in bone tissue engineering. The traditional strategy of
focusing on the reactions of the bone cells is clearly insufficient, as
they do not reflect the in vivo condition, which involves immune
reaction during the process of bone repair. If the importance of the
immune system is neglected, the conclusions will invariably be
drawn when interpreting the results of bone tissue engineering
experiments.
Multiple roles of macrophages in the bone healing
process
Macrophages, among all the immune cells, tend to receive the
most attention due to their multiple roles in the bone healing
process and their high plasticity. Macrophages play a central role
in inflammation and host defense, especially in the innate im-
mune response. Based on distinct functional properties, surface
markers, and inducers, macrophages have been broadly character-
ized into M1 and M2 phenotypes, mirroring the Th1/Th2 nomen-
clature described for T helper cells [55]. M2 macrophages include
three sub-populations: M2a, M2b, and M2c. The inducers, surface
markers and functions of each phenotype are summarized in
Fig. 3. It should be noted that this classification represents only
a simplification of the in vivo scenario. Most likely the macrophage
phenotype occupies a continuum between M1 and M2 designa-
tions, with many shades of activation yet to be identified [56]. This
makes distinguishing M1 from M2 macrophages more difficult
since transient macrophages may possess some characteristics of
both phenotypes, resulting in unreliable surface markers. Thus,
reliance on markers to detect a macrophage population would be
problematic and multiple criteria are required.
There is still no consensus as to which macrophage phenotype is
the most beneficial for osteogenesis. Classically activated inflam-
matory macrophages (M1) are well known to secrete many pro-
inflammatory cytokines (TNFa, IL-6, IL-1b), which are tradition-
ally recognized to induce the osteoclastogenesis, and enhance
osteoclastic activities, leading to bone resorption. However, some
recent studies have found that osteogenesis is enhanced in the
response of M1 macrophages, rather than M2. Guihard et al.,
reported that the classically activated inflammatory M1, but not
M2 macrophages, induced osteogenesis in MSCs via OSM [57].
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FIGURE 3
Inducers, surface markers and functions of macrophage phenotypes. Under the influences of different inducers (next to the arrows), macrophages can
switch into different phenotypes [M1, M2 (M2a, M2b, M2c)]. Each phenotype has special surface markers and different functions.
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which were found to secrete high levels of BMP2, enhancing
osteogenic differentiation of MSCs [46].
Alternative activated M2 macrophages tend to be more closely
associated with late stage of the tissue repair, resulting in either a
fibrocapsule (Fig. 1b) or the formation of new bone (Fig. 1a), by the
secretion of relevant cytokines. They not only contribute osteoin-
ductive and osteogenic cytokines, such as BMP2 and VEGF, to the
process of osteogenesis, but also elaborate inflammatory and
fibrous agents (TNFa, TGF-b1, TGF-b3) to promote pathological
fibrosis [58,59]. In response to excessive inflammation, fibrosis-
enhancing M2 phenotypes would be induced to regulate the
formation of a fibrous capsule, thereby separating the inflamma-
tory reaction center from normal bone tissue. This confines the
inflammation and preserves the normal bone tissue, which would
otherwise lead to failure of bone regeneration (Fig. 1b). An exces-
sive switch to the M2 phenotype, on the other hand, leads to scar
tissue or a delayed wound healing [9,60]. It is, therefore, most
probable that both macrophage phenotypes play indispensable
roles during the bone healing process and that it is the macrophage
switch pattern that determines osteogenesis rather than a specific
macrophage phenotype (Fig. 1).There are only a limited number of studies that have examined
the specific effects of macrophage polarization patterns following
bone injury. Some have investigated the effects of macrophages in
the healing of other tissues such as skin and muscle: one study used
macrophage depletion to determine the effects of immune response
during the sequential stages of skin wound healing [61]. It was found
that depletion of macrophages in the early stage resulted in less scar
formation, whereas depletion of macrophages in the mid-stage
resulted in severe hemorrhage. No effect was noted in the depletion
of macrophages in the late stage. These results indicate diverse roles
of macrophages during various phases of skin repair.
The healing process of bone defects share some commonalities
with wound healing in general. The early stage of the repair response
is dominated by the inflammatory phase, when the majority of
macrophages would be of the pro-inflammatory M1 phenotype.
This stage plays an important role in determining the long-term
success of bone repair, either by promoting a fibrotic foreign body
reaction or by a bone wound healing response with bone matrix
production and vascularization [62]. The M1 macrophages may
determine subsequent immune cell behaviors, either by restraining
the inflammation and initiating the tissue repair, or amplifying the
inflammatory response with subsequent destruction of normal309
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ate early immune environment for activating osteogenesis-enhanc-
ing M2 macrophages, thereby enhancing the new bone
regeneration.
The M2 macrophages play a more prominent role during mid-
to late stages of the repair response compared with M1 macro-
phages. The cytokine release pattern of M2 macrophages is decided
by the M1 polarization during the early phase of bone wound
healing. Prolonged M1 polarization can lead to an increase in
fibrosis-enhancing cytokine pattern released by the M2 macro-
phages, which results in the formation of a fibrocapsule (Fig. 1b).
By contrast, an effective and timely switch in M1 macrophage
phenotype can result in an osteogenesis-enhancing cytokine re-
lease pattern from M2 macrophages and with it the formation of
new bone tissue (Fig. 1a).
Macrophage phenotypes are dynamic and plastic and respond to
environmental cues, allowing these cells to alter their phenotype
and physiology and this accounts for their multiple roles in the bone
healing process [63]. The phenotype switch relates to the type,
concentration and duration of the polarizing signals. When treated
with IL-4, macrophages change into a reparative M2 phenotype
[64]; however, with the addition of LPS and immune complexes,
macrophages can take on a hybrid phenotype possessing both
characteristics of wound-healing and regulatory macrophages
[65]. It is still unclear whether this phenotypic alteration is derived
from the in situ macrophages or a new population of macrophages
migrated from circulating immune cells into the tissue spot to
replace the local cells. Macrophages can be considered as a model
cell type for the evaluation of immune response. In addition, the
heterogeneity and plasticity of macrophages also makes them a
prime target for modulation of immune response. Therefore, more
studies are required to better understand the macrophage switch
pattern and how it affects the bone healing process.
Bone biomaterials modulating the immune response
Bone biomaterials are recognized by the host’s immune system as a
foreign body, arousing multiple directional immune responses. The
biomaterials are not simply passive targets for attacking immune
cells, but elicit significant effects that determine the type and extent
of implant-mediated immune responses. Surface properties, particle
size, porosity, and the released ions from the biomaterials are all
factors involved in these responses (Fig. 4, Table 1).
Surface properties of bone biomaterials
Biological behaviors of immune cells on the surfaces of the bone
biomaterials are largely determined by the surface properties, such
as surface microstructure and wettability [66–68]. Generally, hydro-
phobic materials tend to improve monocyte adhesion in compari-
son to hydrophilic materials resulting in a local immune reaction in
situ [68,69]. It was found that the hydrophilic/neutral copolymer
surfaces inhibited macrophage adhesion and fusion into FBGCs.
However, the adherent cells produced larger amounts of cytokines
(IL-6 and IL-1b) and chemokines [IL-8, RANTES (regulated on
activation, normal T cell expressed and secreted; also known as
CCL5), ENA-78 (epithelial-derived neutrophil-activating peptide
78; also known as CXCL5), and MCP-1 (monocyte chemotactic
protein 1; also known as CCL2)] than the hydrophobic and hydro-
philic ones [66,67].310The surface charge also elicits significant effects on the immune
response. It is generally accepted that cationic (positively charged)
particles are more able to boost inflammatory response than anionic
(negatively charged) and neutral species [70,71]. Most mammalian
cells, including immune cells, have an overall negative surface
charge [72]. The loss of the negative surface charge of the cell
membrane by the positively charged particles may influence protein
localization and confirmation, which, under normal circumstances,
induce signal transduction into the cytoplasm resulting in signifi-
cant biological responses, including inflammatory reaction.
The surface topography of biomaterials is another important
property that affects the interaction of immune cells [73–76]. The
roughness of titanium, for example, affects the attachment and
spread of immune cells: macrophage adhesion increases with time
on all surfaces (polished, machined, and grit-blasted commercially
pure titanium), whereas cell spreading increases with increased
surface roughness [75]. In addition to the effects on cell attach-
ment, the roughness of titanium could also modulate the produc-
tion of inflammatory cytokines and chemokines by macrophages,
with the sandblasting and acid etching surface eliciting significant
stimulatory effects [74].
It is estimated that the surface roughness of bone is around
32 nm, making nanomaterials potentially most biomimic [77].
Nanoscale microstructures have been found to stimulate human
MSCs into producing bone minerals in vitro, even in the absence of
osteogenic supplements. This has generated the considerable inter-
est in the applications of nanomaterials in bone tissue engineering
[78]. It has also been found that micro-structured, rather than
nanostructured topography, induced macrophages to an activated
state that have both M1 and M2 characteristics [79], and titanium
surfaces, modified by titania nanotube arrays, can reduce in vitro
immune response compared to the raw titanium surface [80].
Nanoscale topographic structures may, therefore, prove to be a good
strategy to modulate the immune response of biomaterials.
The underlying mechanisms of biomaterial surface properties
regulating the immune response may be related to how they affect
protein adsorption, such as complement components, fibrinogen,
fibronectin and vitronectin. Upon adsorption, the protein struc-
tures may experience some changes, leading to the exposure of some
masked domains or epitopes, which can then be recognized by host
cells (including immune cells). Binding to these epitopes via specific
receptors allow host cells to attach to the surfaces of the materials
[81]. The initial adsorption of proteins forms a temporal matrix on
the surface, which then becomes an important link between the
material and host response. For this reason, it is important to know
not only what proteins are adsorbed, but also the manner of how
they interact with the surface when determining subsequent beha-
viors of host cells [82]. Both surface chemistry and wettability
influences the conformational changes of adsorbed proteins and
modulate adsorption kinetics, binding strengths, and protein activ-
ities [83]. Most proteins in blood are hydrophilic on their outside
while their hydrophobic domains are turned inwards, thus serum
proteins tend to bind on the hydrophobic surfaces [83,84].
Complement components, fibrinogen, fibronectin and vitronec-
tin have all been found to attach to the implant surfaces and elicit
significant effects on the immune response [85,86]. The comple-
ment system participates in the degradation of implants, mainly by
enhancing phagocytosis of implants and attracting macrophages
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FIGURE 4
Possible properties of bone biomaterials, such as topography, surface charge, wettability particle size, ion release and porosity and pore size, can modulate
the immune cells (macrophages, lymphocytes, etc.) and the subsequent major immune responses (innate, humoral immune response, etc.).
TABLE 1
Surface and bulk properties of biomaterials affecting the immune cells.
Properties of biomaterials Effects on immune cells
Surface properties
Surface wettability Hydrophobic materials enhance monocyte adhesion [68,69]; hydrophilic/neutral surfaces inhibit macrophages
adhesion, but enhance the release of pro-inflammatory cytokines and chemokines [66,67].
Surface charge Cationic particles are more likely to induce inflammation, compared with anionic and neutral species [70,71].
Surface topography, roughness Affect immune cells adhesion [75]; sandblasting and acid etching surfaces elicit significant immune reaction [74].
Particle size Immune cells internalize materials in a size dependent manner [70,102,103]; size affects the immune reaction [70,107–
110], but no consensus on what range of size is more effective.
Porosity and pore size Larger pore size enhance angiogenesis while inhibit inflammation [112,113,116].
Released bioactive ions Some bioactive ions have immunoregulatory effects. Upregulation of inflammation: Ca, Co, Si [124,140,158,159].
Downregulation effects: Ca, Zn, Mg, Sr [125,145,172,178]. Could be in a dose dependent manner.
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complement system is the enzymatic cleavage of C3 into C3b
and C3a, where all three complement pathways (the classical path-
way, the mannose-binding lectin pathway and the alternative
pathway) converge [87]. C3 can be adsorbed to the material surface,
and the adsorption causes conformational changes that make C3
into a C3b-like molecule, which can bind to Bb and become C3
convertase, initiating the alternative pathway [88]. C3b molecules
can themselves bind to the plasma proteins coating the material
surface, triggering the alternative pathway amplification loop,
which produces the majority of the C3b molecules for the normal
functioning of complement system in the implant-mediating im-
mune response [86].
Attachment of plasma fibrinogen exposes the pro-inflammatory
sequence fragment D30, which can bind to the integrin Mac-1(CD11b/CD18) on the surface of phagocytes, participating actively
in the accumulation of phagocytes [85]. Fibrinogen may also
convert to a fibrin-like conformation on material surfaces, facili-
tating the binding and activation of inflammatory cells [85].
Plasma fibronectin is also found to participate actively in the
fusion of FBGCs, thereby modulating the fibrous encapsulation
of implanted materials [89]. Vitronectin can adsorb to a surface in
the face of competition from other plasma proteins [90] and has
been found to be a vital protein adhesion substrate for IL-4-
induced FBGCs formation [91,92].
Adsorption of these proteins from plasma onto biomaterial
surfaces can bind to the integrin receptors on the surface of
immune cells, activating the signaling pathways [85,93–95]. Integ-
rins have been characterized extensively as adhesion receptors
with the capacity of transducing external signals inside cells311
RESEARCH Materials Today  Volume 19, Number 6  July/August 2016
R
E
S
E
A
R
C
H
:
R
eview[96]. It has been suggested that b1 integrin is highly expressed on
the surface of undifferentiated monocytes, while b3 integrin
expression upregulates upon the differentiation of macrophage
[96]. During the formation of FBGCs, both b1 and b2 integrin-
mediated adhesion are present, while b3 integrin-mediated adhe-
sion are not detected, a process that is known to be important in
mediating the adhesion of osteoclasts onto bone surfaces [97]. The
depletion of b3 integrin affects the polarization of macrophages,
switching the phenotype to M2 extreme [98]. Anti-b2 integrin
antibodies can partly block the adhesion of macrophages to the
implants, reducing IL-1b production to basal levels, while anti-b1
and anti-avb3 antibodies have no effect [99]. Macrophage-associ-
ated integrins also participate in regulation of BMP2 expression:
anti-b1 integrin antiserum had a relatively greater effect on mac-
rophage BMP2 mRNA expression than did anti-b3 integrin antise-
rum [75]. Therefore, integrins are likely to play an important role
in transducing the signal from the matrix on implant surfaces to
the immune cells, leading to the cell attachment, spread, division,
and differentiation.
In response to matrix signals integrins can also transmit signals
inside the cell, affecting the cytoskeleton (especially microfila-
ments), thereby altering cell morphology. The correlation of mac-
rophage morphology and inflammatory cytokine production
deriving from the material contact has also been investigated and
macrophages with an amoeboid shape produce more TNFa, com-
pared to macrophages with hemispherical and spherical shapes
[100]. Previous studies have also associated spread morphology with
the level of activation where a decrease in cell spreading indicates a
reduction in the level of activation [76]. The conclusion one can
draw from these findings is that surface properties affect the biolog-
ical behaviors of immune cells by affecting the cytoskeleton. Cyto-
chalasins can bind to actin filaments and block actin polymerization
and elongation, thereby suppressing cytoskeleton-dependent cell
shape remodeling [75,101]. Cytochalasin D was applied to block
polymerization of the actin cytoskeleton and results showed that an
intact cytoskeleton was necessary for the generation of pro-inflam-
matory cytokine IL-1b [99]. Macrophages did not spread but showed
a round shape in response to high concentrations (50 mM) of cyto-
chalasin B, which inhibited the expression of the osteogenesis-
enhancing gene BMP2 [75].
Biomaterials particle size
Immune cells degrade and process particles from implants in a size
dependent manner. Particles less than 0.5 mm in size are internal-
ized by macropinocytosis, clathrin-mediated, caveolin-mediated,
and clathrin/caveolin-independent endocytosis [70,102], whereas
particles larger than 0.5 mm are ingested by phagocytosis [70,103].
Macrophages could phagocytose particles of up to 5 mm [7,13], but
with larger particle size macrophages will coalesce to form FBGCs.
The phagocytosis of microbial pathogens usually results in the
generation of inflammatory cytokines and subsequent pathogen
digestion with lysosomal enzymes [70]. However, it is still unclear
whether the endocytosis of bone biomaterials can activate the
inflammation response, which may vary depending on particle
size and the corresponding endocytosis pathway. Poly(lactic-gly-
colic) acid (PLGA) does not elicit any significant immune response,
although PLGA particles are readily phagocytosed by macro-
phages. By comparison, polystyrene latex elicits a robust release312of inflammatory cytokines (TNFa, TGF-b and nitric oxide) when
ingested by macrophages [104,105].
For same amount of particles, decrease in the particle size
increases the surface area and enhances chemical reactivity, thereby
strengthening the effects on target cells, or even elicit a different
effect altogether [102,106]. Hydroxyapatite particles with the smal-
lest size (1–30 mm) stimulate immune cells to produce the greatest
amount of pro-inflammatory cytokines (TNFa, IL-1b, IL-6) [107].
Bulk gold samples are practically inert, whereas gold nanoparticles
have been reported to be highly reactive for several immune
responses, including production of reactive oxidative species
(ROS) [108]. However, it does not follow that smaller sized particles
necessarily mediate a more severe immune reaction. It has been
found that large (>1 mm) particles can induce a Th1 response,
whereas particles smaller than 0.5 mm) are associated with Th2
[70,109]. An in vivo study has shown that a decrease in the size of
irregularly shaped hydroxyapatite particles inhibits the inflamma-
tory response [110]. A systematic examination of a range of particle
sizes within each class of bone biomaterials is therefore necessary to
quantify how these parameters affect the inflammatory reaction.
Porosity and pore size of biomaterials
Porosity and pore size are two key parameters for the fabrication of
bone tissue engineering scaffolds, which are important in determin-
ing the ingrowth tissue types (inflammatory granuloma tissue,
vascular tissue, bone tissue) [111]. Small pores may severely hamper
the diffusion of nutrients and oxygen supplied from blood and
interstitial fluid, especially in the center of the implant, resulting in
a local hypoxic microenvironment [112]. Hypoxia could enhance
local inflammation, ending up with the formation of granuloma.
This would completely block the small pores, creating a barrier
between the implant and the surrounding bone cells that prevents
bone tissue ingrowth from taking place [113]. In addition, a hypoxic
environment also favors angiogenesis and vascularization by stabi-
lization of hypoxia-inducible factors (HIFs), which is beneficial for
bone regeneration. Proper pore size should be able to induce a
moderate hypoxia environment which can avoid significant inflam-
matory reaction but reserve the angiogenic effects. It has been found
that pores ranging in the size of 90–120 mm hamper vascularization
and leads to chondrogenesis, whereas larger pores (350 mm) en-
hance vascularization and results in higher oxygen tension and
supply of nutrients and enhanced osteogenesis [114].
Higher porosity (80–88%) and macroporosity (pore
size > 50 mm) are thought to be more beneficial for the ingrowth
of bone tissue [111]. Apart from the relevance for the behaviors of
bone cells, the importance of porosity and pore size is demonstrat-
ed in the interaction of implant and host immune system [115]. It
seems that with an increase in pore size, the activity of the foreign
body reaction decreases [113,116]. The underlying mechanism
may be related to macrophage polarization [117–119], since there
appears to be a correlation between increasing fiber/pore size and
upregulated expression of the M2 markers, along with downregu-
lated expression of the M1 markers [117].
Released ions from bone biomaterials
Bioactive bone biomaterials normally undergo degradation to
different extents following implantation, either by physicochemi-
cal dissolution, cell-medicated dissolution, hydrolysis, enzymatic
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terials during degradation can elicit significant effects by altering
the local biological environment [121–123].
Calcium (Ca) is one of the major components of calcium
phosphate bone biomaterials and is well documented to be in-
volved in certain inflammatory signaling pathways [124,125]. The
noncanonical Wnt5A/Ca2+ signaling pathway is found to enhance
inflammation [124]. When Wnt5A binds to Fz5 it can activate the
Wnt/Ca2+ signaling pathway via Ca2+/Calmodulin (CaM)-depen-
dent protein kinase II (CaMKII) and protein kinase C, which
culminates in the upregulation of downstream inflammatory cy-
tokine genes through the transcription factor NF-kB [126]. CaM-
KII, in particular, acts with the cyclic AMP-response element
binding protein (CREB) in macrophages and activates cyclooxy-
genase-2 (COX-2) to produce the proinflammatory hormone pros-
taglandin E2 (PGE2) [127]. High concentration of extracellular
Ca2+ has also been found to be able to activate the calcium sensing
receptor (CaSR) signaling cascade leading to the production of
Wnt5A, which can reduce the expression of TNFa via the inhibi-
tion of NF-kB and downregulate the TNFR1 via the Wnt5a/Ror2
signaling pathway, thereby reducing inflammation [125].
Silicon (Si) is an essential trace element for bone development
[128,129] and is found in active calcification sites during the early
mineralization phase of bone regeneration [130]. Lack of dietary Si
intake leads to deformities in bones [131], whereas dietary Si
supplementation could suppress the bone resorption in ovariec-
tomized animals [132]. Aqueous Si has been reported to improve
the proliferation, differentiation and collagen production of osteo-
blasts [133–135]. Si-containing ionic products released from bio-
active glass, bioceramics and coatings have similar stimulating
effects on regulating the proliferation and differentiation of oste-
oblastic cells [136–139]. A more complex response could be found
in osteoclasts, with Si levels below 30 ppm enhancing the devel-
opment of osteoclasts, while higher levels of Si inhibit develop-
ment of osteoclasts and their bone resorption activities [134]. Si
ions may also elicit an immune reaction, for example, the inhala-
tion of silica particle is the major cause of pneumosilicosis. Nano-
meter sized silica has a milder fibrogenic effects than does
micrometer sized silica, potentially because nanoparticles diffuse
and translocate more readily compared to microparticles [140]. In
addition, it is also thought that long-term exposure to compo-
nents from silicone gel-filled breast implants could be related to
autoimmune or inflammatory diseases, since Si is found at higher
concentrations in the lesions and blood in this patient cohort
[141]. On the other hand, it has been reported that the immuno-
genicity and biocompatibility of flat, nano-channeled, and nano-
porous Si toward human monocytes are almost equivalent to
tissue culture polystyrene, indicating the inertness of Si [142].
Magnesium (Mg) is a biodegradable and biocompatible metal
that is mechanically similar to bone and, therefore, eliminates the
effects of stress shielding and improves in vivo degradation proper-
ties [143]. Mg has been proposed as biodegradable metallic bone
biomaterials for applications in orthopedics [143,144]. Mg2+ ions
can suppress inflammatory cytokine production by inhibiting toll-
like receptor (TLR) pathway [145]. Macrophages recognize foreign
bodies through the TLR pathway, which induce an innate immune
reaction in order to degrade or reject the implants [7]. Most of the
activated TLRs are bound by the adaptor protein MyD88, whichthen activate a downstream cascade [146]. However, TLR3 can only
conduct through a MyD88-independent pathway, using the adap-
tor protein toll-like receptor adaptor molecule (Ticam), also known
as TIR domain containing adapter inducing IFN b (TRIF), whereas
TLR4 can signal through both pathways [147,148]. Although they
produce signals via different adapter proteins, both MyD88-depen-
dent and TRIF-dependent pathways recruit NF-kB eventually, which
then proceed to express inflammatory cytokines [149].
Cobalt (Co) can be used to facilitate angiogenesis by stabilizing
the HIFs and subsequently activating HIF target genes such as
VEGF [150,151]. Accordingly, a number of studies have been
carried in which bone substitute materials were modified with
Co, resulting in the incorporation of Co into tricalcium phos-
phate, 45S5 bioglass1 and mesoporous bioactive glass [152–155].
These bone biomaterials showed significant enhancements of in
vitro angiogenesis; however, in addition to the effects on angio-
genesis, HIF was also found to have some pro-inflammatory
effects. Stabilization of HIF-1a was found to be essential for the
infiltration and activation of myeloid cells in vivo through a
mechanism independent of VEGF [156]. HIF-1a is also required
for the functional maturation of macrophages [157] and pro-
inflammatory cytokines, such as TNFa and IL-1, could stabilize
HIF-1, thereby amplifying the inflammatory response [158,159]. It
is well established that Co ions are toxic and have been implicated
in the failure of joint prostheses [160–162]; its use in biomaterials
is, therefore, controversial.
Zinc (Zn) has been found to stimulate bone formation and
mineralization [163,164] and dietary Zn deficiency can result in
retardation of bone growth [165,166]. Zn has therefore been incor-
porated into CaP biomaterials to enhance their osteogenic capacity.
However, in addition to its positive effects on osteogenesis, it also
regulates the immune response [167]. Zn-substituted ceramics can
increase the release of anti-inflammatory cytokine IL-10, while
reducing the expression of TNFa and IL-1b, which may be due to
the regulation of TLR-4 pathway [168–171]. Patients with inflam-
matory diseases such as rheumatoid arthritis have been found to
present with low blood Zn levels and a corresponding increased
TNFa production [172]; the pathological process can be reversed by
the supplementation of Zn [173]. Zn regulates the immune cell
responses in a concentration-dependent manner: the addition of Zn
salt to peripheral blood mononuclear cells grown in complete
medium led to a concentration-dependent stimulation of TNFa
(peaking at 250 mmol/L) and IL-1b (peaking at 120 mmol/L) [174].
Strontium (Sr) is a physiological trace element that enhances
osteogenesis while inhibiting osteoclastogenesis and has been ap-
plied as a treatment for osteoporosis [175–177]. The underlying
mechanism appears to be related to antagonizing the inflammatory
role of NF-kB, which suggests that Sr is an anti-inflammatory agent
[178]. Studies in which Sr was introduced into Ca/P materials found
that it could inhibit the release of pro-inflammatory cytokine TNFa
in human primary monocytes, at both high (500 mmol/L) and low
(10 mmol/L) ion concentrations [179,180]. Sr has also been shown to
promote cell proliferation and suppress the expression of the pro-
inflammatory cytokines IL-6 in periodontal ligament cells [180,181].
Bioactive ions elicit a range of effects from the immune system,
which differ in composition and concentration. The strategy to
manipulate the immune reaction by controlled release of defined
combinations of bioactive elements is, therefore, one worthy of313
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formed to investigate the mechanisms of how the bioactive ele-
ments affect the immune response, but much work remains to
fully understand the molecular mechanisms that would provide
the basic biological knowledge for the development of bioactive
bone substitute materials.
Definition and evaluation strategy of the
osteoimmunomodulation property of bone
biomaterials
Defining the osteoimmunomodulation property
Bone biomaterials have the capacity to modulate the local im-
mune environment and elicit a significant effect on the function-
ing of bone cells, thereby determining the final outcome of boneFIGURE 5
H&E staining of rat femoral condyle defects four weeks after implantation of b-tr
tricalcium phosphate (CCP) group (b, d, f ) four weeks after implantation. (a) Over
the defect. (b) Overview of the defect treated with CCP; no new bone formation
tissue. The defect size was much larger than b-TCP group. (c) New bone formatio
surrounded the remaining CCP particle. (e) The defect boundary became blurred
was clear and surround by fibrous inflammatory tissue (arrows).
314regeneration and osseointegration. Most of the efforts related to
material-mediated immune responses have focused on whether
the foreign body reaction elicited by the materials would lead to
excessive inflammation and rejection or encapsulation by fibrous
tissue in a concept referred to as ‘biocompatibility’. Immune cells
also release cytokines that regulate osteogenesis, thus inducing or
inhibiting bone formation. Given the importance of immune cells
in bone dynamics, a novel property involving biomaterials, bone
cells, and immune cells together must be defined in an effort to
optimize the development of bone biomaterials. In a recent study
by our laboratory, we investigated how macrophages, in response
to cobalt incorporated b-TCP (CCP) stimulation, affected osteo-
genic differentiation of bone marrow stromal cells (BMSCs) [182].
CCP on its own could enhance the osteogenic differentiation oficalcium phosphate (b-TCP) group (a, c, e) and cobalt incorporated b-
view of the defect filled with b-TCP; new bone formation was observed in
 was observed and the defect was mainly filled by fibrous inflammatory
n on the surface of the remaining b-TCP particle. (d) Inflammatory tissue
 with osteoblasts forming the new bone (arrows). (f ) The defect boundary
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(ALP, OPN, OCN, and COL1). However, when macrophages were
involved, the osteogenic effect was attenuated. We then carried
out an in vivo study to test the accuracy of these testing methods
(Fig. 5). Interestingly, results from biomaterials/bone cells/im-
mune cells are consistent with in vivo findings and are indicative
of the important role of immune cells and macrophages, in
particular, in biomaterial-induced osteogenesis. It further high-
lights the necessity of evaluating the role of the immune response
when considering the in vitro osteogenesis capacity of bone sub-
stitute biomaterials.
The weight of evidence from both the literature and our own
studies, makes it clear that a novel property involving biomater-
ials, bone cells, and immune cells together must be defined and
added to the system of evaluating bone biomaterials in an effort to
optimize the development of such materials. Thus, we propose to
name it osteoimmunomodulation (OIM) in recognition of theFIGURE 6
Contents of the osteoimmunomodulation. Different types of immune cells elicit d
example, due to its multiple roles in bone dynamics and pivotal role in the degr
immune environment that is created by the interaction of biomaterials with imm
inflammatory cytokines, osteogenic and osteoclastogenic factors, and fibriosis en
on bone repair.importance of the immune response during biomaterial-mediated
osteogenesis. In contrast to biocompatibility, OIM does not simply
describe the immune response in relation to the implants, but
focuses more on the effects of the immune environment resulting
from the interaction with biomaterials on the behavior of bone
cells. OIM is a specific property that describes the ability of
biomaterials to alter the local immune environment, affecting
the balance of osteogenesis over osteoclastogenesis, thereby de-
termining the in vivo fate of bone biomaterials in terms of new
bone formation or fibrous encapsulation (Fig. 6). To be specific,
advanced bone biomaterials with favorable OIM are those that can
induce both an adequate and appropriate inflammatory response
by local immune cells, which also release factors that enhance the
recruitment and osteogenic differentiation of BMSCs, resulting in
new bone formation. These materials must further be able to
induce proper osteoclastogenesis, which is important for bone
remodeling and cell-mediating materials degradation, while alsoifferent effects in the bone dynamics. This figure used macrophages as an
adation of bone biomaterials. Osteoimmunomodulation refers to the
une cells and bone cells. Such an immune environment contains
hancing factors, which determines the outcome of bone biomaterial’s effect
315
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FIGURE 7
Suggested evaluation methods for the osteoimmunomodulation. All three
factors (bone biomaterials, immune cells, and bone cells) should be
involved in the system of evaluation. (a) Immune cells first interact with
biomaterial, and then the effects of the created immune environment
(conditioned medium) on osteogenesis/osteoclastogenesis are tested in
bone cells. (b) Bone cells are indirectly contact with immune cells/
biomaterials; the Boyden chambers allows cell migration or molecular
penetration depends on the Boyden chambers pore size. (c) Bone cells and
immune cells are co-cultured on the biomaterials directly.
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properties will cause excessive inflammation, an imbalance of
osteoclastogenesis over osteogenesis and lead to the destruction
of normal bone tissue and the formation of a fibrous capsule. Such
materials would, therefore, be excluded from further preclinical or
clinical testing.
Evaluation of OIM will be challenging, because it involves the
interaction between biomaterials, bone cells, and immune cells
but can be achieved by applying a co-culture system that includes
all three factors. The co-culture systems are outlined below and
would include indirect co-culture using conditioned medium,
indirect co-culture using Boyden chambers, and direct co-culture
(Fig. 7).
Indirect co-culture using conditioned medium
Immune cells are first cultured on bone biomaterials to stimulate
an immune response. The conditioned medium will subsequently
be applied to osteoblastic and osteoclastic cells, to determine its
effects on osteogenesis and osteoclastogenesis, respectively. This
model has the advantage of being a short and simple procedure
[183]. Conditioned media can be frozen down so that the same
batch of medium can be used for several replicates. Not only that,
it can also be applied when immune cells and bone cells are from
different species, thereby extending the range of applications
(direct co-culture system requires the use of cells from the same
species, since immune cells will react to xenogeneous cells and
trigger an unwanted immune reaction). It should be noted that
one potential complication, when comparing to a non-condi-
tioned medium, is the variation in levels of other aspects of the
medium (such as glucose and serum components).
Instead of playing a passive role during the interaction with
immune cells, bone cells actively regulate the immune response.
For example, parathyroid hormone stimulated osteoblasts can
express CXCL12 and IL-7, which are known to regulate B cell
development [184]. Osteoclasts have recently been found to have
innate immune cell properties and participate in the systemic
immune responses [185] by secreting TNF and other cytokines,
such as IL-1, IL-6 and VEGF-C [186,187], thereby auto-amplifying
osteoclastogenesis and enhancing inflammation. MSCs are also
recognized as having immunomodulatory properties that protects
against excessive inflammation [188]. Activated MSCs can induce
the alternative macrophage phenotype M2 [189], which reduces
inflammation and speeds up the healing process. This mechanism
involves the expression of prostaglandin E2 (PGE2) that acts on
macrophages via the prostaglandin EP2 and EP4 receptors
[190,191]. They can also express TNF-a stimulated gene/protein
6 (TSG-6) and IL-1ra to decrease the amplifying effects of pro-
inflammatory cytokines (IL-1, IL-6, and TNF-a) [192,193]. There-
fore, indirect co-culture using Boyden chambers or direct co-
culture can better mimic the in vivo environment, in relation to
the interaction between bone cells and immune cells.
Indirect co-culture using Boyden chambers
The initial phase of the biomaterials/host body reaction is typically
an acute inflammation that results in immune cells attaching to
the surface of the materials before bone cells, which therefore elicit
a greater effect during the early stages of biomaterials mediated
osteogenesis. For this reason, in an indirect co-culture system, the316immune cells can be cultured in indirect contact with the materi-
als and the bone cells in a Boyden chamber insert. The small pore
size (such as 0.4 mm) of the insert keeps the bone cells within the
insert but allows secreted molecules to flow freely. Such an ap-
proach allows for the study of the molecular communications that
results from the interaction between bone cells and immune cells
in relation to the bone biomaterials. Changes to bone cells and
immune cells, including gene and protein expression, can be
investigated separately, which allows for greater resolution in
unraveling the underlying mechanisms. By using larger pore sizes
(3.0 mm or larger depending on the cell size), the migration of bone
cells can also be investigated, to study the effect of chemoattrac-
tant that results from stimulated immune cells.
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Direct co-cultures enable both immune and bone cells to be in
direct contact with the materials at the same time, which would
be the case in an in vivo environment. It can be performed by
layering one cell type on top of another, although this method is
fraught with technical difficulties of which reproducibility of
results is the most prevalent [194]. It requires the involvement
of cells sourced from one individual patient, especially when
immune cells are involved. Primary culture of whole bone marrow
tissue derived from surgery or biopsy may meet the requirement
of providing various types of cells from different tissues, including
skeleton and immune systems. Inter-patient variability and lim-
ited source of suitable donor tissues makes it difficult to establish
this technique as the standard of in vitro evaluation. Another
limitation is separating the effects of the different cell types. The
cells could be sorted by fluorescence-activated cell sorting (FACS)
or magnetic-activated cell sorting (MACS) and then evaluated by
gene expression, but this is fraught with difficulties. Also, the
proteins in the media cannot be ascribed to one particular cell
type. Indirect co-culture using Boyden chambers may, therefore,
be the most suitable and reproducible evaluation system for the
assessment of OIM.
Possible evaluation process of osteoimmunomodulation
As has been pointed out throughout this review, immune cells play
a number of roles during the various phases of bone wound
healing. This implies that the evaluation of OIM must be phase-
oriented. During the early phase, acute inflammation reaction is
predominant and the induced immune environment will decide
the recruitment of MSCs and initiation of osteogenesis. There are
four major events that takes place during the early phase: (1) the
activation of putative inflammation related signaling pathways inTABLE 2
Possible strategies to endow bone biomaterials with favorable oste
Strategies Methods 
Modify the composition Incorporate nutrient elements 
Incorporate bioactive molecules, such a
macrophage inducer (e.g. IL-4, LPS) or in
cytokines (e.g. IL-10, TNFa, IFNg, OSM)
Optimize the fabrication form Immune reaction can be manipulated b
the particle size: from bulk, particle, po
microscale, to nanoscale.
For those fabricated into 3D structured
pore size and porosity should be optim
Change the surface properties Modify the surface topology of materia
roughness)
Modify the surface chemistry of materi
(hydrophility and electric potential)
Others Couple with immunomodulatory drugsresponse to the implants; (2) release of inflammatory cytokines
responsible for the acute inflammation; (3) release of chemokines
and their effect on the recruitments of MSCs; and (4) release of
factors that regulate osteogenesis and fibrosis, which ultimately
will determine the outcome of new bone regeneration.
The mid phase of the repair response is characterized by three
major events: (1) activation of osteogenic signaling pathways in
response to the factors released during the early stage; (2) osteo-
genic differentiation of MSCs that determines the osteogenesis;
and (3) release of osteoclastogenic factors from both immune and
osteoblast cells that accelerates bone remodeling and degradation
of the remaining biomaterials in the late phase.
During the late phase of the repair response the induced im-
mune environment enhances osteoclastogenesis. There are two
major events taking place during the late phase: (1) activation of
osteoclastogenic signaling pathways in response to factors released
during the mid-phase; (2) differentiation of osteoclasts and en-
hanced activity shift the overall balance from osteogenesis toward
osteoclastogenesis. Should there be a failure to activate osteoclas-
togenesis during this phase this may prevent the timely degrada-
tion of biomaterials and impede a proper integration between
bone and materials.
Possible strategies to endow advanced bone
biomaterials with favorable osteoimmunomodulation
It has emerged from both our own and other studies that bone
biomaterials elicit significant effects on the immune system. The
immune response determines subsequent osteogenesis and
osseointegration and is a reflection of the importance of the
immune system to both normal and pathological bone physiolo-
gy. Immune cells, such as macrophages, have a high degree of
plasticity, which makes it possible to modulate the immuneoimmunomodulation.
Examples
Different combinations of nutrient elements (e.g. Mg, Sr,
Si) have been applied to manipulate OIM [148,202].
s
flammatory
OSM has received great attention in osteoimmunology
area, due to its dual effects on regulating both
osteogenesis and osteoclastogenesis [28]. Incorporating
proper dose of OSM can be a valuable strategy to direct
bone regeneration.
y changing
wder,
Inert materials such as gold can become immunogenic
when it is fabricated into nano particles [108].
 scaffolds,
ized.
A uniform 30–40 mm pore size appears to promote the
polarization toward the M2 phenotype [118], whereas
non-porous or random-porous-sized materials appear to
favor the M1 phenotype [196].
ls (size and Material surfaces that provide biomimetic cues, such as
nanoscale structures, have been found to regulate cell/
biomaterial interactions [80,195].
als Macrophages cultured on surfaces with different
hydrophilicity results in different protein expression
profiles and cytokine responses [66].
 The local administration of anti-inflammatory drug
(aspirin) enhances the bone tissue regeneration outcome
via regulating the immune response toward implanted
stem cells and bone substitute materials [53].
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TABLE 3
Glossary of proteins or cytokines appeared in this review.
Abbreviation Name Explanation
TNFa Tumor necrosis factor Pro-inflammatory cytokines.
IFNg Interferon g
IL-1b, 6 Interleukin 1b, 6
IL-1ra, 10 Interleukin-1 receptor antagonist, 10 Anti-inflammatory cytokines.
ROS Reactive oxygen species Natural byproducts from normal metabolism of oxygen
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B
cells
NF-kB is a major transcription factor that regulates genes
responsible for the enhancement of inflammation.
IkB-a Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha
The major function is to inhibit the NF-kB transcription factor.
RANTES Regulated on activation, normal T cell expressed and
secreted; also known as CCL5
Chemokines, participate in cell migrations.
ENA-78 Epithelial-derived neutrophil-activating peptide 78; also
known as CXCL5
MCP-1 Monocyte chemotactic protein 1; also known as CCL2)
Wnt5A Wingless-related MMTV integration site 5A Wnt5A/Ca2+ signaling pathway components.
Fz5 Frizzled-5
CaMKII Calmodulin (CaM)-dependent protein kinase II
CaSR Calcium sensing receptor CaSR signaling cascade leading to reduce inflammation.
RANKL Receptor activator of nuclear factor kappa-B ligand RANKL, an osteoclastogenic factor, binding to RANK, signaling
through AP-1 and NFAT2 to enhance osteoclastogenesis.AP-1 Activator protein 1
NFAT2 Nuclear factor of activated T cells 2
MyD88 Myeloid differentiation primary response gene 88 Toll-like receptor (TLR) pathway components.
Ticam Toll-like receptor adaptor molecule
HIFs Hypoxia-inducible factors Transcription factors that respond to hypoxia microenvironment.
MCSF Macrophage colony-stimulating factor MCSF, an osteoclastogenic factor. MCST binds to c-FMS, signaling
through AKT and MAPK to enhance osteoclastogenesis.c-FMS Colony stimulating factor 1 receptor
AKT Protein Kinase B
MAPK Mitogen-activated protein kinases
OPG Osteoprotegerin A decoy receptor for RANKL, inhibiting osteoclastogenesis.
TRAP Tartrate-resistant acid phosphatase TRAP is largely expressed in osteoclasts and activated
macrophages.
CTSK Cathepsin K It is a lysosomal cysteine protease involved in bone remodeling and
resorption, which is expressed mainly in osteoclasts.
CA 2 Carbonic Anhydrase II CA 2 plays an important role in osteoclast differentiation and bone
resorption by regulating the homeostasis of intracellular pH and
Ca2+.
CT Calcitonin receptor CT binds the peptide hormone calcitonin, involving in bone
formation and metabolism.
MMP9 Matrix metalloproteinase-9 MMP9 is a protease involving in breaking down bone matrix.
TGF b 1/3 Transforming growth factor Enhance the formation of fibrocapsule.
VEGF Vascular endothelial growth factor An angiogenic factor.
WNT10b Wingless-related MMTV integration site 10b A member of WNT family. Can activate canonical WNT pathway and
enhance osteogenesis.
BMP2/6 Bone morphogenetic protein 2/6 An osteogenic factor.
BMPR2 Bone morphogenetic protein receptor type II BMP2 signaling pathway components
BMPR1A Bone morphogenetic protein receptor, type IA
SMAD 1/4/5 Mothers against decapentaplegic homolog 1/4/5
OSM Oncostatin M An inflammatory cytokine; also a regulator of osteoclastogenesis
and osteogenesis.
OSMR Oncostatin M receptor OSMR, A receptor of OSM. Signaling through gp130 and STAT3 to
enhance osteogenesis.gp130 Glycoprotein 130
STAT3 Signal transducer and activator of transcription
ALP Alkaline phosphatase ALP is a byproduct of osteoblast activity. ALP increases when active
bone formation is occurring.
OPN Osteopontin An early indicator of osteogenic differentiation.
OCN Osteocalcin OCN is supposed to be expressed by more mature osteoblastic
phenotypes. Therefore, it is a late indicator of osteogenic
differentiation.
COL1 Collagen type 1 COL1 is another marker of osteogenic differentiation, which will be
increased when the osteogenesis is enhanced.
IBSP Bone sialoprotein 2 IBSP is a significant component of the bone extracellular matrix.
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wresponse by manipulating the materials’ composition or structure.
Potential strategies for such manipulations are (Table 2): (1) modi-
fying the surface topology of materials (size and roughness) – material
surfaces that provide biomimetic cues, such as nanoscale struc-
tures, have been found to regulate cell/biomaterial interactions
[80,195]; (2) modifying the surface chemistry of materials (hydrophi-
lity and electric potential) – macrophages cultured on surfaces
with different hydrophilicity results in different protein expres-
sion profiles and cytokine responses [66]; (3) changing the particles
size – the immune response varies with the change of material
sizes, even though the composition remains unchanged; (4) opti-
mizing pore size and porosity – a uniform 30–40 mm pore size appears
to promote the polarization toward the M2 phenotype [118],
whereas non-porous or random-porous-sized materials appear to
favor the M1 phenotype [196]; (5) incorporating nutrient elements
[148,197] – the immune response can be manipulated by a com-
bination of bioactive elements (e.g. Ca, Mg, Sr, Co, Zn) in a
controlled-release manner; (6) incorporating bioactive molecules
[198] such as macrophage inducers (e.g. IL-4, LPS) or inflammatory
cytokines (e.g. IL-10, TNFa, IFNg); and (7) coupling with immuno-
modulatory drugs [199,200], for example inflammatory modulation
drug (steroid and non-steroidal anti-inflammatory drugs). These
strategies should all be considered when designing biomaterials,
since their combination can have synergistic effects. Needless to
say, a better understanding of the mechanisms underlying the
immune response and their effects on osteoclastogenesis and
osteogenesis is essential for developing advanced bone biomater-
ials with favorable OIM properties (Table 3).
Of these strategies, modifying the biomaterials with nutrient
elements may have the greatest potential, not least because nutri-
ent elements are fundamental for human physiology. The inte-
gration of nutrient elements into biomaterials has already been
widely applied to modify materials in an effort to improve their
bioactivity. For example, incorporating strontium into bioactive
glasses inhibits osteoclast activity and enhances the osteogenesis
and has, therefore, expanded the application of hydroxyapatite to
patients with osteoporosis [177,201]. The scientific literature clear-
ly reveals that nutrient elements can elicit significant effects on
immune response regulation depending on the concentration and
combination of the various elements. The implication of this is the
possibility of finding an optimal combination of nutrient elements
such that one can obtain an advanced bone biomaterial with
multiple functions, one of which is OIM. Based on this strategy,
we recently combined the elements Sr, Mg, and Si, to fabricate two
novel bioceramic coating materials (Sr2MgSi2O7, MgSiO3). Both
materials were found to endow the inert titanium substrate (Ti–
6Al–4V) with favorable OIM and reduce inflammation and osteo-
clastogenesis, while maintaining or enhancing osteogenic capaci-
ty compared with hydroxyapatite coated materials [148,202].
These are promising results that highlight the feasibility of this
strategy and also that the design and preparation of bone bioma-
terials must be done with OIM properties in mind.
Conclusions
Bone biomaterials can determine an immune response. The type of
response is related to the properties of the biomaterials, such as
surface topography, particle size, porosity and pore size, and ion
release. Components from the degraded materials and releasedmolecular signals from the interaction between immune system
and implants, significantly affect the biological behaviors of bone
cells, thereby determining the bone regeneration outcome. Ac-
cordingly, OIM is proposed to define this process, which involves
the interaction between biomaterials, immune cells and bone
cells, thus emphasizing the importance of immune cells during
the biomaterial-mediated osteogenesis. Biomaterials with the ap-
propriate OIM can create an immune environment that enhances
osteogenesis, and regulates proper osteoclastogenesis that can
participate in the bone remodeling and cell-mediated materials
degradation. Such a property is important for the development of
advanced immunomodulatory bone biomaterials. Biomaterials
with poor OIM may cause excessive inflammation and lead to
an imbalance of osteoclastogenesis over osteogenesis; such mate-
rials would, therefore, be excluded from further tests. Future
studies should focus on determining the kind of immune envi-
ronment that is conducive for osteogenesis and osseointegration,
thus providing a set of design aims for the modification of bone
biomaterials. Understanding how the biomaterials modulate the
immune environment can guide the development of modification
strategies, and integral to this enterprise is a systematic evaluation
of modification strategies to explore an optimized modification
strategy to endow advanced bone biomaterials with favorable
OIM.
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